Home › Diffuse Large B-Cell Lymphoma › Oregon
Diffuse Large B-Cell Lymphoma clinical trials in Oregon
15 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in Oregon.
Cities in Oregon
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8001), Eugene
- Kaiser Permanente Interstate Medical Office - Central ( Site 0181), Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Providence Portland Medical Center ( Site 0120), Portland
- Providence Oncology and Hematology Clinic Westside ( Site 0179), Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT06890884Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Oncology Associates of Oregon, P.C, Eugene
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06806033Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Providence Hood River Memorial Hospital, Hood River
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06649812A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Oregon Health & Science University (OHSU), Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07226843Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Oregon Health and Science University ( Site 1004), Portland
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Oct 30, 2026 · NCT06395103Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Oncology Associates of Oregon, Eugene
- Oregon Health and Science University, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06500273Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT05890352Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT05633615Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06784167Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Oregon Health and Science University Knight Cancer Institute, Portland
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- Oregon Health and Science University Knight Cancer Institute, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
- OHSU Knight Cancer Institute, Portland
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jul 7, 2026 · NCT06249191A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Oregon Health & Science University, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2025 · NCT05780034From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.